Toxic epidermal necrolysis associated with nivolumab treatment for head
and neck cancer
Nivolumab is used for patients with recurrent/metastatic head and neck
cancer resistant to platinum. We report a 76-year-old man with squamous
cell carcinoma of the tongue, who developed toxic epidermal necrolysis
(TEN) after nivolumab treatment. TEN is a fatal disease, and early
treatment of the adverse events are important.